Statement: There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 16/149 (10.74%)   Anaemia 0/149 (0.00%)   Febrile neutropenia 7/149 (4.70%)   Neutropenia 1/149 (0.67%)   Pancytopenia 1/149 (0.67%)   Atrial fibrillation 2/149 (1.34%)   Cardiac failure congestive 0/149 (0.00%)   Abdominal pain 0/149 (0.00%)   Diarrhoea 2/149 (1.34%)   Dyspepsia 0/149 (0.00%)   Gastritis haemorrhagic 0/149 (0.00%)   Nausea 2/149 (1.34%) Adverse Events 2:   Total: 20/151 (13.25%)   Anaemia 1/151 (0.66%)   Febrile neutropenia 4/151 (2.65%)   Neutropenia 2/151 (1.32%)   Pancytopenia 0/151 (0.00%)   Atrial fibrillation 0/151 (0.00%)   Cardiac failure congestive 1/151 (0.66%)   Abdominal pain 1/151 (0.66%)   Diarrhoea 3/151 (1.99%)   Dyspepsia 1/151 (0.66%)   Gastritis haemorrhagic 1/151 (0.66%)   Nausea 1/151 (0.66%)
Secondary_evidence: Adverse Events 1:   Total: 5/95 (5.26%)   Febrile neutropenia 0/95 (0.00%)   Neutropenia 0/95 (0.00%)   Atrial fibrillation 0/95 (0.00%)   Pleuropericarditis 0/95 (0.00%)   Vomiting 0/95 (0.00%)   Pryexia 0/95 (0.00%)   Anaphylactic shock 1/95 (1.05%)   Gastroenteritis 0/95 (0.00%)   Fibula fracture 1/95 (1.05%)   Tibia fracture 1/95 (1.05%)   Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2:   Total: 3/20 (15.00%)   Febrile neutropenia 0/20 (0.00%)   Neutropenia 0/20 (0.00%)   Atrial fibrillation 1/20 (5.00%)   Pleuropericarditis 1/20 (5.00%)   Vomiting 0/20 (0.00%)   Pryexia 0/20 (0.00%)   Anaphylactic shock 0/20 (0.00%)   Gastroenteritis 1/20 (5.00%)   Fibula fracture 0/20 (0.00%)   Tibia fracture 0/20 (0.00%)   Intervertebral disc protrusion 1/20 (5.00%)